Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 2
2009 2
2010 6
2011 6
2012 5
2013 4
2014 1
2015 2
2016 2
2017 5
2018 1
2019 3
2020 5
2021 8
2022 8
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Vaccine response in people with multiple sclerosis treated with fumarates.
Tremblay MA, Vukusic S, Shanmugasundaram M, Bozin I, Levin S, Gocke A, Wipfler P. Tremblay MA, et al. Among authors: wipfler p. Mult Scler J Exp Transl Clin. 2023 Sep 6;9(3):20552173231191170. doi: 10.1177/20552173231191170. eCollection 2023 Jul-Sep. Mult Scler J Exp Transl Clin. 2023. PMID: 37692293 Free PMC article. Review.
Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics.
Salmanton-García J, Wipfler P, Leckler J, Nauclér P, Mallon PW, Bruijning-Verhagen PCJL, Schmitt HJ, Bethe U, Olesen OF, Stewart FA, Albus K, Cornely OA; VACCELERATE Consortium. Salmanton-García J, et al. Among authors: wipfler p. Travel Med Infect Dis. 2024 Jan-Feb;57:102676. doi: 10.1016/j.tmaid.2023.102676. Epub 2023 Dec 6. Travel Med Infect Dis. 2024. PMID: 38061408 Free article.
Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F, Seiberl M, Bieler L, Moser T, Kleindienst W, Wallner-Essl W, Koelblinger P, Wipfler P, Harrer A. Otto F, et al. Among authors: wipfler p. Eur J Neurol. 2024 Jul;31(7):e16279. doi: 10.1111/ene.16279. Epub 2024 Mar 31. Eur J Neurol. 2024. PMID: 38556899 Free PMC article.
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh G, Gradl C, Heschl B, Hegen H, Di Pauli F, Assar H, Leutmezer F, Traxler G, Krajnc N, Zulehner G, Hiller MS, Rommer P, Wipfler P, Guger M, Enzinger C, Berger T; AUT-MuSC investigators. Bsteh G, et al. Among authors: wipfler p. Eur J Neurol. 2022 Jul 5:10.1111/ene.15488. doi: 10.1111/ene.15488. Online ahead of print. Eur J Neurol. 2022. PMID: 35791496 Free PMC article.
56 results